title: Sodium glucose cotransporter 2 inhibitors.
abstract: SGLT2 inhibition offers a novel mechanism to mitigate hyperglycemia in patients with diabetes and the introduction of SGLT2 has added a significant new tool to the antihyperglycemic armamentarium. At present, 2 agents are approved for use in the United States and several more are in development. SGLT2 inhibitors are generally associated with a reduction in A1C of between 0.5% and 1%. SGLT2 inhibitors are associated with an increased incidence of urinary tract and genital infections but these infections are typically mild, responsive to treatment, and are not use limiting.
authors.affiliation: Department of Pharmacotherapy, Washington State University, Health Sciences Building, Suite 210, PO Box 1459, Spokane, WA 99210, USA. Electronic address: whitej@wsu.edu.
authors.forename: John R
authors.initials: JR
authors.lastname: White
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism; D016903:Drug Monitoring / Q000379:methods; D005947:Glucose / Q000378:metabolism*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism; D051297:Sodium-Glucose Transporter 2 / Q000378:metabolism; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D016896:Treatment Outcome
chemical_list: D005947:Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
keywords: Antihyperglycemic agents; SGLT2; SGLT2 inhibitors; Sodium glucose cotransporter 2; Type 2 diabetes